ImmuCell to delay resubmission of FDA application for Re-Tain
ICCC Stock | USD 4.89 0.10 2.00% |
About 61% of ImmuCell's investor base is looking to short. The analysis of the overall investor sentiment regarding ImmuCell suggests that many traders are alarmed. The current market sentiment, together with ImmuCell's historical and current headlines, can help investors time the market. In addition, many technical investors use ImmuCell stock news signals to limit their universe of possible portfolio assets.
ImmuCell |
ImmuCell said it is delaying resubmission of its market application to the US Food and Drug Administration for its dairy cattle medication Re-Tain by one month. Read more here.
Read at seekingalpha.com
ImmuCell Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards ImmuCell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ImmuCell Fundamental Analysis
We analyze ImmuCell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuCell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
ImmuCell is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
ImmuCell Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmuCell stock to make a market-neutral strategy. Peer analysis of ImmuCell could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics with similar companies.
Peers
ImmuCell Related Equities
PTIX | Protagenic Therapeutics | 5.77 | ||||
CVKD | Cadrenal Therapeutics, | 4.55 | ||||
FENC | Fennec Pharmaceuticals | 1.32 | ||||
HCWB | HCW Biologics | 0.75 | ||||
ANEB | Anebulo Pharmaceuticals | 0.64 | ||||
ACOGF | Alpha Cognition | 0.35 | ||||
TRGNF | Transgene | 0.00 | ||||
XOMAO | XOMA | 0.39 | ||||
LCTX | Lineage Cell | 0.43 | ||||
TPST | Tempest Therapeutics | 0.45 | ||||
LIPO | Lipella Pharmaceuticals | 1.32 | ||||
RZLT | Rezolute | 1.39 | ||||
MNOV | MediciNova | 1.74 | ||||
ELYM | Eliem Therapeutics | 1.90 | ||||
ONTTF | Oxford Nanopore | 4.88 |
Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |